What Patient Factors Predict Physicians' Decision Not to Treat Latent Tuberculosis Infection in Tuberculosis Contacts?

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Dobler, Claudia C ^a,b   Luu, Queenie ^b   Marks, Guy B ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BIRTHPLACE; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HOUSEHOLD; HUMAN; IMMIGRATION; INFANT; INFECTION RISK; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NEWBORN; PHYSICIAN ATTITUDE; PREDICTION; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT REFUSAL; TUBERCULIN TEST; TUBERCULOSIS;

CASE-CONTROL STUDIES; COHORT STUDIES; CONTACT TRACING; FEMALE; HUMANS; LATENT TUBERCULOSIS; LOGISTIC MODELS; MALE; NEW SOUTH WALES; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; SEX FACTORS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84884807694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076552     Document Type: Article

References (37)

1. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221-247.
2. Dobler CC, Marks GB, (2013) Risk of tuberculosis among contacts in a low-incidence setting. Eur Respir J 41: 1459-1461.
3. Dobler CC, (2013) What do we know about the outcomes of tuberculosis contact investigations in NSW? N S W Public Health Bull 24: 34-37.
4. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, et al. (1999) Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353: 444-449.
5. Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM, (2010) Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 14: 1112-1119.
6. Ferebee SH, (1970) Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26: 28-106.
7. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr, (2011) Priorities for screening and treatment of latent tuberculosis infection in the United States. American Journal of Respiratory & Critical Care Medicine 184: 590-601.
8. Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M, (2008) Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 12: 498-505.
9. Dobler CC, Flack JR, Marks GB, (2012) Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open 2: e000666.
10. Dobler CC, McDonald SP, Marks GB, (2011) Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One 6: e29563.
11. Kopanoff DE, Snider DE Jr, Caras GJ, (1978) Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117: 991-1001.
12. Nolan CM, Goldberg SV, Buskin SE, (1999) Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281: 1014-1018.
13. Kunst H, Khan KS, (2010) Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 14: 1374-1381.
14. Menzies D, (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159: 15-21.
15. NSW Department of Health (2005) Policy directive on preventive therapy. Available: http://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_072.pdf. Accessed 2013 Jul 5.
16. Lohmann EM, Koster BF, le Cessie S, Kamst-van Agterveld MP, van Soolingen D, et al. (2012) Grading of a positive sputum smear and the risk of Mycobacterium tuberculosis transmission. Int J Tuberc Lung Dis 16: 1477-1484.
17. Moran-Mendoza O, Marion SA, Elwood K, Patrick DM, FitzGerald JM, (2007) Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts. Int J Tuberc Lung Dis 11: 1014-1020.
18. Hirsch-Moverman Y, Tsiouris S, Salazar-Schicchi J, Colson PW, Muttana H, et al. (2006) Physician attitudes regarding latent tuberculosis infection: international vs. U.S. medical graduates. Int J Tuberc Lung Dis 10: 1178-1180.
19. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698-702.
20. Sterne JA, Rodrigues LC, Guedes IN, (1998) Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 2: 200-207.
21. Menzies D, (2000) What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? Clin Infect Dis 31Suppl 3: S71-74.
22. Johnson H, Lee B, Doherty E, Kelly E, McDonnell T, (1995) Tuberculin sensitivity and the BCG scar in tuberculosis contacts. Tuber Lung Dis 76: 122-125.
23. Marks GB, Bai J, Simpson SE, Sullivan EA, Stewart GJ, (2000) Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. Am J Respir Crit Care Med 162: 1851-1854.
24. Almeida LM, Barbieri MA, Da Paixao AC, Cuevas LE, (2001) Use of purified protein derivative to assess the risk of infection in children in close contact with adults with tuberculosis in a population with high Calmette-Guerin bacillus coverage. Pediatr Infect Dis J 20: 1061-1065.
25. Santiago EM, Lawson E, Gillenwater K, Kalangi S, Lescano AG, et al. (2003) A prospective study of bacillus Calmette-Guerin scar formation and tuberculin skin test reactivity in infants in Lima, Peru. Pediatrics 112: e298.
26. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-952.
27. Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S, (1989) Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Reports 104: 151-155.
28. Connolly M, Nunn P, (1996) Women and tuberculosis. World Health Stat Q 49: 115-119.
29. Barry C, Waring J, Stapledon R, Konstantinos A, (2012) Tuberculosis notifications in Australia, 2008 and 2009. Commun Dis Intell 36: 82-94.
30. Uplekar MW, Rangan S, Weiss MG, Ogden J, Borgdorff MW, et al. (2001) Attention to gender issues in tuberculosis control. Int J Tuberc Lung Dis 5: 220-224.
31. Jimenez-Corona ME, Garcia-Garcia L, DeRiemer K, Ferreyra-Reyes L, Bobadilla-del-Valle M, et al. (2006) Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area. Thorax 61: 348-353.
32. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW, (2008) Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 12: 1235-1254.
33. Dobler CC, Marks GB, (2012) Completion of Treatment for Latent Tuberculosis Infection with Monthly Drug Dispensation Directly through the Tuberculosis Clinic. PLoS One 7: e48900.
34. Colson PW, Hirsch-Moverman Y, Bethel J, Vempaty P, Salcedo K, et al. (2013) Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis 17: 473-479.
35. Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J, (2004) Health care workers and the initiation of treatment for latent tuberculosis infection. Clin Infect Dis 39: 667-672.
36. Bhanot N, Haran M, Lodha A, Paul V, Goswami R, et al. (2012) Physicians' attitudes towards self-treatment of latent tuberculosis. Int J Tuberc Lung Dis 16: 169-171.
37. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 60: 555-564.